Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01992094 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older
A Phase 3 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,680
- Enrollment target
NCT01992094: Completed Phase 3 study, sponsored by Novartis Vaccines.
NCT01992094 is a Phase 3 study that has completed, run by Novartis Vaccines. The registered enrollment target is 2,680 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (247% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01992094, a Phase 3 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,680 participants
- Enrollment target
Study Summary
Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.
Primary Outcome
Immunogenicity of QIVc to comparator TIVc (For H1N1, H3N2 and B1 strain, the comparison is between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison is between QIVc and TIV2c) was assessed in terms of GMT in subjects measured by hemagglutination inhibition (HI) assay, three weeks after vaccination with one dose of either QIVc or TIV1c and TIV2c. Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV1c or TI
Interventions
- BIOLOGICAL QIVc
- BIOLOGICAL TIV1c
- BIOLOGICAL TIV2c
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,680 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
What the finished NCT01992094 record still lists
NCT01992094 is an interventional study that assigns participants to a tested intervention. Its 2,680 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (247% higher).
The record links to 0 conditions, and to 3 interventions - of which QIVc is the first listed.
NCT01992094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01992094 about?
NCT01992094 is a clinical study titled "Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older". Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.
What is the current status of trial NCT01992094?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,680 participants. The study started on 2013-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01992094?
The interventions under investigation include: QIVc (BIOLOGICAL), TIV1c (BIOLOGICAL), TIV2c (BIOLOGICAL).
Who is sponsoring clinical trial NCT01992094?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01992094's enrollment target sits among peer trials
2,680 84th of 2000 higher than 1,917 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05471908 · 2,674 participants · NA
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia